Treatment of SARS-CoV-2 induced pneumonia with NAD+ in a mouse model

Yisheng Jiang, Yongqiang Deng, Tiantian Ma, Huanhuan Pang, Zeping Hu, Cheng Qin, Zhiheng Xu

(Institute of Genetics and Developmental Biology, Chinese Academy of Sciences; Beijing Institute of Microbiology and Epidemiology; School of Pharmaceutical Science)

Preprint Published on October 30, 2020 – by Research Square
This article, posted by Research Square, says that:

  • The global COVID-19 epidemic has spread rapidly around the world and has already caused the death of more than one million people. As there is yet no vaccine, it is urgent to develop effective strategies to treat COVID-19 patients.…”  (emphasis added)
  • …We therefore investigated the effect of treatment with NAD+ and found that the pneumonia phenotypes, including excessive infiammatory cell infiltration and embolization in SARS-CoV-2 infected lungs were significantly rescued by boosting NAD+ levels. Most notable, cell death was suppressed substantially (>65%) by NAD+ supplementation" (emphasis added)
  • …These results indicate that NAD+ supplementation can protect the lung from infiammatory injury, including cell death, caused by SARS-Cov-2 infection in both old and young mice..." (emphasis added)
  • …Therefore, our study is in strong support of initiating a trial for treating COVID-19 patients with NAD+ or its precursors...." (emphasis added)

Read the full article